Seres Therapeutics MCRB Cash Flow Statement (2014-2026)

NASDAQ MCRB
$5.13 -0.15 (-2.84%)
As of: Sep 10, 2026 · 3:52 PM EDT
Reported Financials

Seres Therapeutics Quarterly Cash Flow Statement

Periods 49 quarters
Latest Jun 2026

Seres Therapeutics reported cash from operations of -$22.39M and free cash flow of -$22.39M for the quarter ended Jun 2026, down 68.5% year over year. This cash flow statement covers 49 quarters of results from Jun 2014 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
68.25M-49.69M-56.28M-64.43M-59.97M-2.20M-71.48M48.06M-48.85M-41.58M-40.64M-34.31M111.29M-28.40M-26.62M-24.34M-21.86M-18.93M-20.58M-21.09M
Share-based Compensation
10.90M5.67M14.82M14.99M14.91M73.22M16.83M16.76M16.37M5.09M19.16M19.31M19.12M3.77M2.82M2.34M2.48M3.20M1.77M1.74M
Gains from Investment Securities
-0.13M-1.01M-0.41M-0.42M-0.13M
Asset Writedowns and Impairment
3.27M5.81M
Cash from Operations
127.74M-51.86M-66.44M-49.90M-59.58M-52.89M-76.58M65.98M-59.26M-47.50M-35.24M-39.81M-34.68M-38.88M26.91M-13.29M2.21M-14.71M-16.36M-22.39M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles
-0.52M1.60M-0.31M-0.23M-0.13M-0.01M0.19M0.05M
Amortization of Deferred Charges
0.83M0.98M1.06M1.25M1.25M1.67M2.07M2.18M2.20M2.42M2.39M2.39M2.44M2.01M2.04M2.06M2.12M2.19M2.25M1.95M
Depreciation & Amortization (CF)Depreciation & Amortization
1.49M1.55M1.57M1.69M1.75M1.63M1.40M1.53M1.68M1.63M1.56M1.42M1.40M1.08M1.08M1.06M1.04M0.95M0.78M0.67M
Change in Working Capital
Change in Receivables
-0.00M-1.25M0.35M-0.19M0.08M0.04M
Change in Inventory
5.34M13.19M11.12M12.33M11.02M10.45M
Change in Account Payables
3.10M4.58M-6.46M7.17M-3.96M5.45M-3.81M0.71M-3.45M-5.04M1.59M-0.41M0.04M-4.16M-1.97M0.08M-0.52M0.01M0.66M-1.15M
Change in Accured Expenses
38.56M0.07M-3.69M5.43M1.20M0.40M-19.03M9.35M-1.06M26.58M-4.24M10.09M-9.10M-6.94M-4.44M-0.35M0.63M-2.35M-1.04M0.94M
Other Working Capital Changes
-1.17M-1.36M-1.51M-0.62M-1.39M-0.68M-0.07M-0.51M-1.06M-0.56M-0.22M-2.04M-2.11M-1.97M-2.09M-2.11M-2.18M-2.29M-2.47M-12.32M
Investing Activities
Capital Expenditures
4.09M1.58M2.95M2.16M1.25M3.46M4.07M1.23M1.80M0.88M0.06M0.10M0.13M0.09M0.06M0.16M0.01M0.03M
Change in Acquisitions & Divestments
43.60M43.64M44.08M33.54M41.38M21.47M11.23M11.75M
Cash from Investing Activities
25.11M13.19M12.97M23.40M40.13M5.93M2.74M10.52M-1.80M-0.88M-0.06M1.30M141.14M-0.09M-0.03M-0.18M-0.01M0.18M0.01M
Financing Activities
Other financing activities
0.17M0.17M0.89M0.88M1.23M0.92M0.35M0.13M0.18M0.05M0.27M0.03M
Debt Issuance and Repayment
Long-Term Debt Issuances
0.95M27.61M103.38M127.91M
Change in Capital Stock
Net Shares Issued and Repurchased
3.60M3.64M4.53M2.12M2.51M6.74M7.82M0.48M0.55M0.59M
Net Equity Issued and Repurchased
-3.28M4.24M7.49M18.41M3.38M-1.48M1.00M12.17M0.40M1.72M
Misc.
Cash from Financing Activities
0.61M-0.78M26.85M0.13M98.03M4.60M5.66M58.18M1.44M6.43M18.76M-110.87M1.74M1.18M0.06M12.66M0.43M1.72M
Exchange Rate Effect
-0.00M-0.00M0.00M0.00M-0.00M
Change in Cash
153.46M-39.46M-26.62M-26.37M78.58M-42.37M-68.19M134.68M-59.61M-41.95M-16.54M-38.51M-4.41M-37.23M28.06M-13.47M2.26M-1.87M-15.93M-20.66M
Free Cash Flow
123.65M-53.44M-69.39M-52.06M-60.83M-56.35M-80.65M64.75M-61.05M-48.38M-35.30M-39.91M-34.81M-38.97M26.86M-13.45M2.20M-14.74M-16.36M-22.39M
Net Cash Flow
153.46M-39.46M-26.62M-26.37M78.58M-42.37M-68.19M134.68M-59.61M-41.95M-16.54M-38.51M-4.41M-37.23M28.06M-13.47M2.26M-1.87M-15.93M-20.66M